RECEIVED CENTRAL FAX CENTER

FAX TRANSMISSION

DEC 2 3 2005

DATE: December 23, 2005

PTO IDENTIFIER: Application Number 09/975,253-Conf. #8837

Patent Number

Inventor: Moore et al.

US Patent and Trademark Office MESSAGE TO:

FAX NUMBER: (571) 273-8300

HUMAN GENOME SCIENCES, INC. FROM:

Mark J. Hyman

PHONE: (240) 314-1224

Attorney Dkt. #: PF196P1

PAGES (Including Cover Sheet):

CONTENTS:

Three Month Request for Extension of Time Under 37 CFR 1.136(a) (1 page)

Nonce of Appeal (I page)

Processing Fee Transmutal charging \$130.00 to deposit account (1 page)

Request to Correct Inventorship in a Patent Application Under 37 C.F.R. § 1.48(a)(1) (2 pages) Statement of Craig A. Rosen Under 37 C.F.R. § 1.48(a)(2) (1 page)

Executed Supplemental Declaration (1 page in 3 counterparts)

Supplemental Application Data Sheet (3 pages)

Statement of Human Genome Sciences, Inc. Under 37 C F.R. §§ 3.73 and 1.48(a)(5) (2 pages)

Statement of Johns Hopkins University Under 37 C.F.R. §§ 3.73 and 1.48(a)(5) (2 pages)

Certificate of Transmission (1 page)

If your receipt of this transmission is in error, please notify this firm immediately by collect call to sender at (240) 314-1224 and send the original transmission to us by return mail at the address below.

This transmission is intended for the sole use of the individual and entity to whom it is addressed, and may contain information that is privileged, confidential and exempt from disclosure under applicable law. You are hereby notified that any dissemination, distribution or duplication of this transmission by someone other than the intended addressee or its designated agent is strictly prohibited.

HUMAN GENOME SCIENCES, INC.

Intellectual Property Dept., 14200 Shady Grove Road, Rockville, Maryland 20850 Telephone: 240-314-4400 Facsimile: 301-309-8439

PTO/SB/97 (08-04)
Approved for use through 07/31/2006 OMB 0651-0031
U.S. Parent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no descent are contributed to respond to a collection of information unless a deplays a valid OMB control mumber

Application No. (if known): 09/975,253

Attornéy Docket No : PF196P1

Certificate of Transmission under 37 CFR 1.8

I hereby certify that this correspondence is being facsimile transmitted to the United States Patent and Trademark Office.

December 23, 2005 Date

From-HGS INTELLECTUAL PROPERTY DEPT

Signature Mark J. Hyman Typed or printed name of person signing Certificate 46,789 (240) 314-1224 Telephone Number Registration Number, if applicable

Note:

Each paper must have its own certificate of transmission, or this certificate must identify each submitted paper

Three Month Request for Extension of Time Under 37 CFR 1.136(a) (1 page)

Notice of Appeal (1 page)

Processing Fee Transmittal charging \$130.00 to deposit account (1 page) Request to Correct Inventorship in a Patent Application Under 37 C.F.R. § 1.48(a)(1) (2 pages)

Statement of Craig A. Rosen Under 37 C.F.R. § 1.48(a)(2) (1 page) Executed Supplemental Declaration (1 page in 3 counterparts)

Supplemental Application Data Sheet (3 pages)

Statement of Human Genome Sciences, Inc. Under 37 C.F.R. §§ 3.73 and

1.48(a)(5) (2 pages)

Statement of Johns Hopkins University Under 37 C.F.R. §§ 3.73 and 1.48(a)(5) (2 pages)

PTO/SB/17/ (04-05)
Approved for use through 7/31/2007. OM/9 0651-0031
U.S. Paters and Trademark Office, U.S. DEPARTMENT OF COMMERCE
to 8 CONSCION of information unless it displays a valid OMB control outlibre.

Under the Pagerwork Reduction Act of 1995, no person are required	io respond to a collection of informat	tion unless it displays a valid Oline control number	
PROCESSING FEE Under 37 CFR 1.17(i) TRANSMITTAL. (Fees are subject to annual revision) Send completed form to: Commissioner for Patents P.O. Box 1450 Alexandra, VA 22313-1450	Application Number	09/975,253-Conf. #8837	
	Filing Date	October 12, 2001	
	First Named Inventor	Paul A. Moore HECEIVEL	
	Art Unit	1647 CENTRAL FAX CEN	TER
	Examiner Name	S. L. Wegen DEC 2 3 2005	j
	Aπorney Docket Number	PF196P1	•

Enclosed is a paper filed under 37 CFR Payment of \$ 130.00 Is enclosed. This form should be included with the above-ment is applicable. For transmittal of polition fees under	loned paper and	that requires a processing fee (37 CFR 1.17(i)). faxed or mailed to the Office using the appropriate Mail Stop. (g) or (n), see form PTO/SB/17p.
The Commissioner is hereby authorized x processing fee under 37 CFR Enclose a duplicative copy of this form to	to charge the tol 1.17(i) x for tee processir	lowing fees to Deposit Account No. 08-3425 : any deficiency of fees and credit of any overpayments ag.
Payment by credit card (Form PTO-2038	g ot edminajeut et	nclosed). Do not provide credit card information on this form.
Processing Fees under 37 CFR 1.17(i): Fee		ee Code 1808 for all, scept for §1.221 papers (Fee Code 1803)
	shtor or inventors ar	ter the filing date without an eath or declaration as prescribed
by \$1.63, except in provisional application § 1.48 – for correcting inventorship, except in provision § 1.52(q) = for processing a nonprovisional application § 1.53(b)(3) – to convert a provisional application file § 1.55 – for entiry of late priority papers § 1.71(g)(2) – to unter an amendment to the specific § 1.99(q) = for processing a belated submission unid § 1.103(b) – for requesting limited suspension of act § 1.103(c) – for requesting limited suspension of act § 1.103(d) – for requesting deterred examination of a § 1.217 – for processing at reducted copy of a paper the patent application publication § 1.221 – for requesting voluntary publication or replies § 1.231(g)(5) – for processing a second or supsequent	ns. onal applications on filed with a special under § 1.53(c) in application for purposes of § 1.99 ion. continued proston, continued proston, request for contian application, submitted in the hie phication of an application of the sair to 35 U.S.C. 371(c)	ato a nonprovisional application under §1 53(b) of 35 U.S.C. (103(c)(2) if not filed within the cited time periods ecusion application (§ 1 53(d)) inued examination (§ 1 114). of an application in which a redacted copy was submitted for ication. Fee Code 1803 me real party in interest. c)(4) naming an inventive entity different from the inventive
by § 1.63, except in provisional application § 1.48 – tor correcting inventorship, except in provision § 1.52(d) – tor processing a nonprovisional applicant § 1.53(b)(3) – to convert a provisional applicant § 1.55 – tor entry of late priority papers § 1.71(g)(2) – to unter an amendment to the specific § 1.79(e) – for processing a bolated submission unde § 1.103(b) – for requesting limited suspension of actit § 1.103(d) – for requesting limited suspension of actit § 1.103(d) – for requesting limited examination of a 5.103(d) – for requesting deterred examination of a 5.1.217 – for processing a reducted copy of a paper the patient application publication § 1.221 – for requesting voluntary publication or reputational for requesting voluntary publication or reputational for thing an oath or declaration pursuant empty set forth in the international stage § 3.81 – for a patent to issue to assignee, assignment	ns. onal applications on filed with a special under § 1.53(c) in application for purposes of § 1.99 ion. continued proston, continued proston, request for contian application, submitted in the hie phication of an application of the sair to 35 U.S.C. 371(c)	tication in a language other than English into a nonprovisional application under §1 53(b) of 35 U.S.C. 103(c)(2) if not filled will'in the cited time periods acuson application (§ 1 53(d)) inside examination (§ 1 114). I of an application in which a redacted copy was submitted for incation. Fee Code 1803 The real party in interest. (3)(4) naming an inventive entity different from the inventive
by § 1.63, except in provisional application § 1.48 – tor correcting inventorship, except in provision § 1.52(d) – tor processing a nonprovisional applicant § 1.53(b)(3) – to convert a provisional application file § 1.55 – tor entry of late priority papers § 1.71(g)(2) – to unter an amendment to the specific § 1.799(e) – for processing a belated submission unde § 1.103(b) – for requesting limited suspension of active § 1.703(d) – for requesting limited suspension of active § 1.703(d) – tor requesting deterred examination of § 1.217 – for processing a reducted copy of a paper the patient application publication § 1.221 – for requesting voluntary publication or reputation of the patient application of the patient application of the patient application or reputation of the patient application of the patient application or reputation of the patient application of the patient application or reputation of the patient application application of the patient application appli	ns. onal applications on filed with a special under § 1.53(c) in application for purposes of § 1.99 ion. continued proston, continued proston, request for contian application, submitted in the hie phication of an application of the sair to 35 U.S.C. 371(c)	tication in a language other than English ito a nonprovisional application under §1 53(b) of 35 U.S.C. 103(c)(2) if not filed within the cited time periods ecusion application (§ 1 53(d)) inside examination (§ 1 114). I of an application in which a reducted copy was submitted for ecation. Fee Code 1803 instread to real party in interest. (2)(4) naming an inventive entity different from the inventive agrinent of the issue tee.

12/27/2005 TL0111 00000057 083425 09975253

03 FC:1464 130.00 DA

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:

Moore et al.

Docket No.: PF196P1

用ECEIVED CENTRAL FAX CENTER

Conf. No.: 8834

DEC 2 3 2005

U.S. Patent Application No.: 09/975,253

Filed: October 12, 2001

Art Unit: 1647

Title: Methods and Compositions for Treating and Preventing Infection Using Human

Interferon Regulatory Factor 3

Examiner: S. Wegert

REQUEST TO CORRECT INVENTORSHIP IN A PATENT UNDER 37 C.F.R. § 1.48(a)(1)

Commissioner for Parents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Applicants hereby request to correct inventorship in the above-captioned nonprovisional patent application for which an oath or declaration has already been filed. Specifically, applicants request to change the inventorship in this patent from Paul A. Moore, and Paula Pitha to Paul A. Moore, Paula Pitha, and Craig A. Rosen.

This request to correct inventorship is accompanied by:

- A statement from each person to be added as an inventor that the inventorship (1)error occurred without any deceptive intention on his or her part;
- An oath or declaration by the actual inventor or inventors as required by 37 C.F.R. § 1.63 or as permitted by 37 C.F.R. §§ 1.42, 1.43 or § 1.47, with a Supplemental Application Data Sheet;
- A written consent of the assignee or assignees of the originally named (3) inventors: and
 - The fee set forth in 37 C.F.R. § 1.17(i). (4)

If any further action by Applicants is required, please call the undersigned at the phone number provided below. If there are any additional fees due in connection with the filing of this paper, please charge the fees to our Deposit Account No. 08-3425.

Dated: December 23, 2005

Respectfully submitted,

Mark J. Hyman

Registration No.: 46,789

HUMAN GENOME SCIENCES, INC.

14200 Shady Grove Road Rockville, Maryland 20850

(240) 314-1224

MJH/KC

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:

Docket No.: PF196P1

RECEIVED

Moore et al.

CENTRAL FAX CENTER

Application No.: 09/975,253

Confirmation No.: 8837

DEC 2 3 2005

Filed: October 12, 2001

Art Unit: 1647

For: Methods and Compositions for Treating and Preventing Infection Using Human Interferon

Examiner: S. L. Wegert

Regulatory Factor 3

STATEMENT OF CRAIG A. ROSEN UNDER 37 C.F.R. § 1.48(a)(2)

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

I was erroneously omitted as an inventor of the above-captioned patent application.

This error in inventorship occurred without any deceptive intention on my part.

Date:

Craig A. Rosen

22400 Rolling Hill Lane Laytonsville, MD 20882

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:

Moore et al.

Docket No.: PF196P1

RECEIVED CENTRAL FAX CENTER

DEC 23 2005

Application No.: 09/975,253

Filed: October 12, 2001

.....

For: Methods and Compositions for Treating and Preventing Infection Using Human Interferon

Regulatory Factor 3

Confirmation No.: 8837

Art Unit: 1647

Examiner: S. L. Wegert

STATEMENT OF HUMAN GENOME SCIENCES, INC. UNDER 37 C.F.R. §§ 3.73 AND 1.48(a)(5)

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Statement Under 37 C.F.R. § 3.73

Human Genome Sciences, Inc. ("HGS"), organized and existing under the laws of the State of Delaware, having its principal place of business at 14200 Shady Grove Road, Rockville, Maryland 20850, states that it is an assignee of record of less than the entire right, title and interest for the above-identified patent application by virtue of an assignment from inventor Moore recorded in the U.S. Patent and Trademark Office on March 27, 2002 at Reel 012742, Frame 0673. The extent (by percentage) of HGS' ownership is 50% (1 of 2 inventors). Once the request to correct inventorship submitted herewith is granted, HGS will remain an assignee of less than the entire right, title and interest for the above-identified patent application; the extent (by percentage) of its ownership will be 66.67% (2 of 3 inventors).

The undersigned, whose title is supplied below, is empowered to sign this document on behalf of HGS.

Statement Under 37 C.F.R. § 1.48(a)(5)

In accordance with the Request to Correct Inventorship submitted herewith, HGS agrees to the proposed change of inventorship adding Craig A. Rosen as an inventor of the above-captioned patent

For:	Human Genome Sciences, Inc	
Signat	ture: Carne HD-	
Name	:: James H. Davis, Ph.D.	
	Executive Vice President and General Counsel	
Date:		

4021

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:

Docket No.: PF196P1

HECEIVED CENTRAL FAX CENTER

Moore et al.

Dec-23-05 04:14pm

Application No.: 09/975,253

Confirmation No.: 8837

DEC 2 3 2005

Filed: October 12, 2001

Art Unit: 1647

For: Methods and Compositions for Treating and

Preventing Infection Using Human Interferon

Regulatory Factor 3

Examiner: S. L. Wegert

STATEMENT OF JOHNS HOPKINS UNIVERSITY UNDER 37 C.F.R. §§ 3.73 AND 1.48(a)(5)

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Statement Under 37 C.F.R. § 3.73

Johns Hopkins University ("JHU") states that it is an assignee of record of less than the entire right, title and interest for the above-identified patent application by virtue of an assignment from inventor Pitha recorded in the U.S. Patent and Trademark Office on March 27, 2002 at Reel 012742, Frame 0469. The extent (by percentage) of JHU's ownership is 50% (1 of 2 inventors). Once the request to correct inventorship submitted herewith is granted, JHU will remain an assignee of less than the entire right, title and interest for the above-identified patent application; the extent (by percentage) of its ownership will be 33.33% (1 of 3 inventors).

The undersigned, whose title is supplied below, is empowered to sign this document on behalf of JHU.

Statement Under 37 C.F.R. § 1.48(a)(5)

In accordance with the Request to Correct Inventorship submitted herewith, JHU agrees to the proposed change of inventorship adding Craig A. Rosen as an inventor of the above-captioned patent

For: <u>Joh</u>	ns Hopkins University		
Signature:	RYTRI		
-			
Name:	R. Keith Baker, Ph.D.		_
	Sr. Director, Technology Licenship		
Title:			
Date:	4/22/05	· ,	
			•